Review



recombinant prdx5  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress recombinant prdx5
    Recombinant Prdx5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+prdx5/10__4103_slash_mgr__medgasres___d___25___00353-57-0-3?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant prdx5 - by Bioz Stars, 2026-08
    94/100 stars

    Images



    Similar Products

    recombinant prdx5  (MedChemExpress)
    94
    MedChemExpress recombinant prdx5
    Recombinant Prdx5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+prdx5/10__4103_slash_mgr__medgasres___d___25___00353-57-0-3?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant prdx5 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    recombinant prdx5 protein  (ChinaPeptides)
    90
    ChinaPeptides recombinant prdx5 protein
    Target identification of MY in protecting oxidative damage in TBHP‐treated C2C12 myotubes. (A) The structure of the probe MY‐P. (B) Pull‐down labeling with MY‐P in C2C12 myotubes. CBB: Coomassie Brilliant Blue. (C) Volcano plot of MY‐P binding proteins compared with control group (10 µM MY‐P). (D) Pull‐down/Western blotting identified the target protein <t>PRDX5.</t> (E) The PRDX5 expression in Gast muscle from young or aged mice. ## p < 0.01, young versus aged. ** p < 0.01, aged versus aged+MY.L. && p < 0.01, aged versus aged+MY.H. (F) The PRDX5 expression in TBHP‐treated C2C12 myotubes. ## p < 0.01, vehicle versus TBHP, * p < 0.05, ** p < 0.01, MY versus TBHP. (G) ITC titration of MY (100 µM) into recombinant PRDX5 protein (5 µM). (H) Western blotting‐based CETSA validation of thermal stabilization of PRDX5 in response MY treatment at the concentration from 0 to 100 µM. β‐Actin was used as a control. Data are displayed as mean ± SD, n = 6.
    Recombinant Prdx5 Protein, supplied by ChinaPeptides, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+prdx5/pmc11167181-266-7-12?v=ChinaPeptides
    Average 90 stars, based on 1 article reviews
    recombinant prdx5 protein - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Target identification of MY in protecting oxidative damage in TBHP‐treated C2C12 myotubes. (A) The structure of the probe MY‐P. (B) Pull‐down labeling with MY‐P in C2C12 myotubes. CBB: Coomassie Brilliant Blue. (C) Volcano plot of MY‐P binding proteins compared with control group (10 µM MY‐P). (D) Pull‐down/Western blotting identified the target protein PRDX5. (E) The PRDX5 expression in Gast muscle from young or aged mice. ## p < 0.01, young versus aged. ** p < 0.01, aged versus aged+MY.L. && p < 0.01, aged versus aged+MY.H. (F) The PRDX5 expression in TBHP‐treated C2C12 myotubes. ## p < 0.01, vehicle versus TBHP, * p < 0.05, ** p < 0.01, MY versus TBHP. (G) ITC titration of MY (100 µM) into recombinant PRDX5 protein (5 µM). (H) Western blotting‐based CETSA validation of thermal stabilization of PRDX5 in response MY treatment at the concentration from 0 to 100 µM. β‐Actin was used as a control. Data are displayed as mean ± SD, n = 6.

    Journal: MedComm

    Article Title: Myricanol prevents aging‐related sarcopenia by rescuing mitochondrial dysfunction via targeting peroxiredoxin 5

    doi: 10.1002/mco2.566

    Figure Lengend Snippet: Target identification of MY in protecting oxidative damage in TBHP‐treated C2C12 myotubes. (A) The structure of the probe MY‐P. (B) Pull‐down labeling with MY‐P in C2C12 myotubes. CBB: Coomassie Brilliant Blue. (C) Volcano plot of MY‐P binding proteins compared with control group (10 µM MY‐P). (D) Pull‐down/Western blotting identified the target protein PRDX5. (E) The PRDX5 expression in Gast muscle from young or aged mice. ## p < 0.01, young versus aged. ** p < 0.01, aged versus aged+MY.L. && p < 0.01, aged versus aged+MY.H. (F) The PRDX5 expression in TBHP‐treated C2C12 myotubes. ## p < 0.01, vehicle versus TBHP, * p < 0.05, ** p < 0.01, MY versus TBHP. (G) ITC titration of MY (100 µM) into recombinant PRDX5 protein (5 µM). (H) Western blotting‐based CETSA validation of thermal stabilization of PRDX5 in response MY treatment at the concentration from 0 to 100 µM. β‐Actin was used as a control. Data are displayed as mean ± SD, n = 6.

    Article Snippet: The protein sample, complexed by MY and recombinant PRDX5 protein (synthesized by ChinaPeptides, Shanghai, China), was dialyzed into the ITC buffer overnight.

    Techniques: Drug discovery, Labeling, Binding Assay, Control, Western Blot, Expressing, Titration, Recombinant, Biomarker Discovery, Concentration Assay

    MY protects C2C12 myotubes against oxidative damage through targeting PRDX5. (A) Protein expression levels of PRDX5, MuRF1, UNG1, and Nrf2 in si‐ Prdx5 and scrambled cells. β‐Actin was used as a loading control. (B) Protein expression level of nuclear Nrf‐2 in si‐ Prdx5 and scrambled cells. Histone H3 was used as the loading control. LDH level (C) and ATP concentration (D) in TBHP‐treated scrambled and si‐ Prdx5 cells. (E) Mitochondrial content in TBHP‐treated scrambled and si‐ Prdx5 cells, assessed by MitoTracker Green staining. (F) Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in TBHP‐treated scrambled and si‐ Prdx5 cells, assessed by Seahorse assay. (G) The levels of coprecipitated Nrf2 and UNG1 with PRDX5 in C2C12 myotubes. Data are displayed as mean ± SD, n = 6. # p < 0.05, ## p < 0.01, vehicle versus TBHP. * p < 0.05, ** p < 0.01, TBHP+MY versus TBHP. & p < 0.05, && p < 0.01, si‐ Prdx5 +MY versus scrambled+MY.

    Journal: MedComm

    Article Title: Myricanol prevents aging‐related sarcopenia by rescuing mitochondrial dysfunction via targeting peroxiredoxin 5

    doi: 10.1002/mco2.566

    Figure Lengend Snippet: MY protects C2C12 myotubes against oxidative damage through targeting PRDX5. (A) Protein expression levels of PRDX5, MuRF1, UNG1, and Nrf2 in si‐ Prdx5 and scrambled cells. β‐Actin was used as a loading control. (B) Protein expression level of nuclear Nrf‐2 in si‐ Prdx5 and scrambled cells. Histone H3 was used as the loading control. LDH level (C) and ATP concentration (D) in TBHP‐treated scrambled and si‐ Prdx5 cells. (E) Mitochondrial content in TBHP‐treated scrambled and si‐ Prdx5 cells, assessed by MitoTracker Green staining. (F) Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in TBHP‐treated scrambled and si‐ Prdx5 cells, assessed by Seahorse assay. (G) The levels of coprecipitated Nrf2 and UNG1 with PRDX5 in C2C12 myotubes. Data are displayed as mean ± SD, n = 6. # p < 0.05, ## p < 0.01, vehicle versus TBHP. * p < 0.05, ** p < 0.01, TBHP+MY versus TBHP. & p < 0.05, && p < 0.01, si‐ Prdx5 +MY versus scrambled+MY.

    Article Snippet: The protein sample, complexed by MY and recombinant PRDX5 protein (synthesized by ChinaPeptides, Shanghai, China), was dialyzed into the ITC buffer overnight.

    Techniques: Expressing, Control, Concentration Assay, Staining

    Cys100 of PRDX5 is critical for binding to MY. (A) Binding sites of MY–PRDX5 by virtual docking analysis. (B) The PRDX5 expression level in PRDX5‐WT and PRDX5‐C100A overexpression C2C12 cell lines, respectively. (C) ROS production. (D) ATP concentration. (E) Protein expression levels of MuRF1, UNG1 and Nrf2 in TBHP‐treated PRDX5‐WT and PRDX5‐C100A overexpression cells. β‐Actin was used as a loading control. (F) Protein expression level of nuclear Nrf‐2 in TBHP‐treated PRDX5‐WT and PRDX5‐C100A overexpression cells. Histone H3 was used as the loading control. Data are shown as mean ± SD, n = 6. # p < 0.05, ## p < 0.01, vehicle versus TBHP. * p < 0.05, ** p < 0.01, TBHP+MY versus TBHP. & p < 0.05, && p < 0.01, WT+MY versus C100+MY. $ p < 0.05, $$ p < 0.01, TBHP versus MY+TBHP.

    Journal: MedComm

    Article Title: Myricanol prevents aging‐related sarcopenia by rescuing mitochondrial dysfunction via targeting peroxiredoxin 5

    doi: 10.1002/mco2.566

    Figure Lengend Snippet: Cys100 of PRDX5 is critical for binding to MY. (A) Binding sites of MY–PRDX5 by virtual docking analysis. (B) The PRDX5 expression level in PRDX5‐WT and PRDX5‐C100A overexpression C2C12 cell lines, respectively. (C) ROS production. (D) ATP concentration. (E) Protein expression levels of MuRF1, UNG1 and Nrf2 in TBHP‐treated PRDX5‐WT and PRDX5‐C100A overexpression cells. β‐Actin was used as a loading control. (F) Protein expression level of nuclear Nrf‐2 in TBHP‐treated PRDX5‐WT and PRDX5‐C100A overexpression cells. Histone H3 was used as the loading control. Data are shown as mean ± SD, n = 6. # p < 0.05, ## p < 0.01, vehicle versus TBHP. * p < 0.05, ** p < 0.01, TBHP+MY versus TBHP. & p < 0.05, && p < 0.01, WT+MY versus C100+MY. $ p < 0.05, $$ p < 0.01, TBHP versus MY+TBHP.

    Article Snippet: The protein sample, complexed by MY and recombinant PRDX5 protein (synthesized by ChinaPeptides, Shanghai, China), was dialyzed into the ITC buffer overnight.

    Techniques: Binding Assay, Expressing, Over Expression, Concentration Assay, Control